feed,title,long_url,short_url
MedRxiv,Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19,https://medrxiv.org/cgi/content/short/2021.11.30.21266756v1?rss=1,https://j.mp/3G7Aql0
